New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
UP AFTER EARNINGS: Panera Bread (PNRA), up 1.3%... Zeltiq Aesthetics (ZLTQ), up 28.1%... Rubicon Project (RUBI), up 12.5%... RingCentral (RNG), up 11%... Endocyte (ECYT), up 10.5%... Aegerion Pharmaceuticals (AEGR), up 9.4%... Examworks (EXAM), up 8.8%... U.S. Steel (X), up 7.3%... Edwards Lifesciences (EW), up 7.2%... Sequenom (SQNM), up 7.5%... NuVasive (NUVA), up 5.6%... NCR Corp. (NCR), up 3.5%... Amgen (AMGN), up 4% after reporting quarterly results and announcing that it will reduce its global workforce by 12%-15%... Trinity Industries (TRN), up 2.8%... Twitter (TWTR), up 29.1% after reporting better than expected second quarter results as well as third quarter and fiscal 2014 guidance above analyst expectations. NOTABLE: Weibo Corp (WB), up 5.5%; Yelp (YELP), up 3.6%; Facebook (FB), up just under 1%, respectively, following Twitter's second quarter results. ALSO HIGHER: Intercept Pharmaceuticals (ICPT), up 2.5% following upgrade to Buy from Neutral at Nomura. DOWN AFTER EARNINGS: Buffalo Wild Wings (BWLD), down 10.6%... Move Inc. (MOVE), down 3.5%... Aflac (AFL), down 4% after reporting second quarter results and guidance for third quarter and fiscal 2014. ALSO LOWER: TherapeuticsMD (TXMD), down marginally after filing to sell $40M in common stock.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
November 18, 2015
07:42 EDTICPTIntercept PBC treatment revenue likely to beat expectations, says Oppenheimer
Subscribe for More Information
05:55 EDTFBFacebook partners with Airtel Africa to bring free basics to 17 countries
In an announcement on Facebook, CEO Mark Zuckerberg said, "In South Africa , we announced with Airtel Africa that we will be bringing free basic services to all 17 countries where they operate. first launched in Zambia and today half of the 30 countries with Free Basics are in Africa. These new launches will bring free services to Burkina Faso, Chad, Gabon, Madagascar, Niger, Nigeria, Republic of the Congo, Sierra Leone and Uganda. We also recently partnered to launch a satellite to provide internet coverage to remote areas of Sub-Saharan Africa starting in 2016. We've also partnered with the Praekelt Foundation to give developers the tools they need to build free basic services to reach people just coming online. Connecting people across the African continent is critical to our mission. We're going to keep pushing forward to develop new ways to bring people online until the whole world is connected." Reference Link
November 17, 2015
16:01 EDTFBOptions Update; November 17, 2015
iPath S&P 500 VIX Short-Term Futures up 1.32 to 21.07. Option volume leaders: GE BAC AAPL FB NFLX SYF WMT CSCO MU SUNE VRX BABA AMZN HD FCX
09:35 EDTFBActive equity options trading on open: AAPL FB GE HD
Subscribe for More Information
08:04 EDTZLTQ, TXMDStifel to hold a conference
Subscribe for More Information
07:56 EDTRUBIUBS to hold a conference
Global Technology Conference is being held in San Francisco on November 16-18 with webcasted company presentations to begin on November 17 at 10:45 am.; not all company presentations may be webcasted. Webcast Link
November 16, 2015
16:05 EDTAMGNAmgen to present eight IMLYGIC abstracts
Subscribe for More Information
16:00 EDTFB, TWTROptions Update; November 16, 2015
Subscribe for More Information
12:58 EDTTWTRStocks with call strike movement; VXX TWTR
Subscribe for More Information
11:59 EDTZLTQZELTIQ to host analyst and investor day
Analyst and Investor Day to be held on New York on November 17 at 9:30 am. Webcast Link
11:16 EDTRUBIRubicon Project management to meet with Oppenheimer
Meeting to be held in New York on November 18 hosted by Oppenheimer.
11:15 EDTRNGRingCentral management to meet with Oppenheimer
Meeting to be held in Texas on November 18 hosted by Oppenheimer.
10:36 EDTYELPYelp management to meet with Sterne Agee CRT
Meeting to be held in San Francisco on November 16 hosted by Sterne Agee CRT.
09:59 EDTFBOmega bought Valeant in Q3, sold some SuneEdison
Leon Cooperman's Omega Advisors gave a quarterly update on its stakes in a filing this morning, disclosing its positions as of September 30. NEW STAKES: Pfizer (PFE), Valeant (VRX) Walgreens Boots Alliance (WBA), TerraForm Global (GLBL), Cigna (CI). INCREASED STAKES: Google Class A (GOOGL), Facebook (FB), Delta Air Lines (DAL). DECREASED STAKES: SunEdison (SUNE), Shire (SHPG), Citi (C), KAR Auction (KAR), LyondellBasell (LYB). LIQUIDATED STAKES: McKesson (MCK), 21st Century Fox (FOXA), General Motors (GM), QEP Resources (QEP), eBay (EBAY).
09:37 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL FB ORCL BAC SUNE FDX FCX EXPE NFLX MU AMZN INTC TSLA
09:01 EDTNCRFirst Data, NCR Corp. sign strategic commercial agreement
First Data (FDC) and NCR Corporation (NCR) have entered into a strategic commercial agreement. First Data will be a preferred provider of cybersecurity and payment processing solutions to NCR's customers in the grocery, petroleum and convenience store industries. NCR will be a preferred provider of ATM hardware and services to First Data's client base of more than 4,000 financial institutions. The companies will also pursue co-development of integrated commerce technology solutions for U.S. merchant clients.
05:38 EDTXU.S. Steel implied volatility of 102 at upper end of index mean range
November 15, 2015
17:54 EDTFBFacebook to expand use of 'Safety Check' feature in wake of Paris attacks
Facebook announced it will be expanding its use of "Safety Check," a feature allowing users of the social network who live in endangered areas of the world to let friends and family know they are safe. Traditionally limited to natural disasters, the policy change has been made in the wake of the terrorist attacks on Paris, France, during which the company turned on Safety Check for affected users. The move spurred both praise for quick action and criticism for not using the feature during other serious events such as Thursday's tragedy in Beirut, prompting Facebook to reconsider its use of the service. "Each time we have launched the tool, we've improved it... We are learning to make the tool and policies behind it better as we go -- and because Safety Check is a relatively new feature for us, we're still understanding how it can best be used... We talked with our employees on the ground, who felt that there was still a need that we could fill. So we made the decision to try something we've never done before: activating Safety Check for something other than a natural disaster... We want this tool to be available whenever and wherever it can help," explained the company.
15:08 EDTICPTIntercept reports analysis of Phase 3 obeticholic acid study, other data
Intercept announced results from three studies in primary biliary cirrhosis, recently renamed primary biliary cholangitis, for presentation at the American Academy for the Study of Liver Diseases annual meeting. The studies evaluate investigational use of obeticholic acid, Intercept's lead farnesoid X receptor agonist. In a presentation titled, "Clinical Epidemiology of Primary Biliary Cirrhosis based on a Large U.S. Laboratory Database: Incidence and Trends in Serum Alkaline Phosphatase," an analysis of a clinical database of more than 575,000 patients who received an anti-mitochondrial antibody test showed that, of those patients, 6,107 were classified as having probable PBC based on a positive AMA test and ALP greater than the upper limit of normal at any time prior to AMA testing or up to one month following AMA testing. The study found that 69% of those likely PBC patients continued to have elevated ALP two years after the first positive AMA test. Meanwhile, a presentation titled "A Trial-Based Model of Liver Transplant and Liver-Related Death in Patients with Primary Biliary Cirrhosis" includes an analysis of data from the Phase 3 POISE trial of OCA in PBC using the UK-PBC predictive model of transplant-free survival based on ALP, bilirubin, alanine transaminase, albumin and platelet count. Risk was assessed at 5, 10 and 15 years based on a 12-month change from baseline in patients treated with OCA plus or minus ursodiol or placebo plus or minus ursodiol at the end of the POISE study. The UK-PBC risk algorithm showed a significantly lower risk of liver transplant or liver-related death in OCA-treated patients compared to placebo. Lastly, a presentation titled "Physician versus Patient Perceptions of Medical Care Quality in Primary Biliary Cirrhosis" showed that patients may not be properly informed about their ALP scores and the nature of PBC symptoms.
14:38 EDTICPTIntercept reports analyses of OCA in fatty liver patients
Intercept Pharmaceuticals announced new results from the non-invasive evaluation of liver fibrosis in patients from the FLINT trial of obeticholic acid, or OCA, for the treatment of nonalcoholic steatohepatitis, or NASH. In the trial, treatment with once daily 25 mg OCA was shown to reverse fibrosis in a "significant proportion" of biopsy-proven NASH patients, as observed by repeat liver biopsy at the end of the double-blind treatment phase at week 72, according to the company. Post-hoc analysis evaluated the early predictive value of three known non-invasive fibrosis tests -- FIB-4, APRI and NFS -- in identifying patients who experienced improvement in fibrosis. Each was assessed at baseline and over the course of treatment and then correlated with histologic changes observed in the OCA and placebo patients. The analysis demonstrated that OCA treatment of NASH patients led to a statistically significant decrease in FIB-4 from baseline as compared to placebo. Further, a decline in FIB-4 of 10% after 24 weeks of treatment predicted improvement in fibrosis by at least one stage as assessed by biopsy at 72 weeks, according to Intercept. Similarly, OCA-treated patients experienced a significant decrease in APRI as compared to placebo, and a 34% reduction in APRI at 24 weeks predicted improvement in fibrosis by at least one stage at 72 weeks. On average, OCA treatment reduced the FIB-4 score to less than 1.3 and the APRI score to less than 0.5, the respective cut-off values associated with advanced fibrosis, while placebo patients remained above these cut-offs. While NFS declined in the OCA-treated patients and increased in the placebo patients, it did not appear to be sensitive to changes in fibrosis, the company said.
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use